On The Pen GLP-1 News

On The Pen GLP-1 News

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.


Den här podcasten är hämtad från ett öppet RSS-flöde och publiceras inte av Podme. Den kan innehålla reklam.

Avsnitt(208)

Ozempic Personality With Dr Spencer Nadolsky

Ozempic Personality With Dr Spencer Nadolsky

This conversation dives headfirst into one of the most controversial and least understood side effects of GLP-1 medications, what many are now calling the “Ozempic personality.” In this candid intervi...

19 Apr 42min

Foundayo GLP-1 Pill: FDA Needs More Data

Foundayo GLP-1 Pill: FDA Needs More Data

Orforglipron (also known as Foundayo) is one of the most promising drugs in the GLP-1 space, notably as only the second oral GLP-1 option for obesity. Unlike injectable treatments, it does not require...

14 Apr 20min

GLP-1 Access Is EXPLODING… But Something Else Is Happening

GLP-1 Access Is EXPLODING… But Something Else Is Happening

If you just look at the headlines, things look great for access to GLP-1 medications but for some of those already using these medications things are changing and getting tighter. Listen in as Dave br...

7 Apr 23min

Zepbound Dosing: What Your Doctor Didn't Explain

Zepbound Dosing: What Your Doctor Didn't Explain

Are you on tirzepatide or semaglutide and struggled with inconsistent weight loss and side effects? On this episode of On The Pen, Dave Knapp and Dr. Ian Ellis dive into the surprising variability of ...

2 Apr 1h 13min

Wegovy Price Drop Exposes a Bigger Problem

Wegovy Price Drop Exposes a Bigger Problem

A major shift in obesity treatment is underway following a surprising pricing move that could change how patients access care. This episode explores the growing divide between traditional healthcare a...

31 Mars 18min

 Retatrutide Is Too Good… And That’s The Problem

Retatrutide Is Too Good… And That’s The Problem

Access to compounded and research-grade GLP-1s may be tightening, as comments from Robert F. Kennedy Jr. signal increased enforcement and a push back toward branded medications. At the same time, new ...

24 Mars 29min

MASSIVE: Compound Tirzepatide and Semaglutide Updates!

MASSIVE: Compound Tirzepatide and Semaglutide Updates!

On The Pen breaks down the latest GLP-1 news, compounded semaglutide updates, tirzepatide controversy, FDA and DDC list developments, Novo Nordisk findings, Eli Lilly B12 tirzepatide concerns, and new...

17 Mars 26min

Cheap Zepbound Incoming for Medicare,  But CMS Just Issued a Catch

Cheap Zepbound Incoming for Medicare, But CMS Just Issued a Catch

Send a textOn this episode of the podcast, host Dave Knapp breaks down the latest updates on potential GLP-1 receptor agonists coverage for people on Medicare living with obesity. With new guidance re...

10 Mars 20min

Populärt inom Hälsa

somna-med-henrik
rss-jossan-nina
rss-bara-en-till-om-beroende-medberoende
inga-beiga-morsor
rss-vuxna-pa-latsas
bullfika
not-fanny-anymore
rss-viktmedicinpodden
sexnoveller-deluxe
johannes-hansen-podcast
angestpodden
sa-in-i-sjalen
sova-med-dan-horning
rss-hos-psykologen
rss-angra-inget-3
rss-basta-livet
rss-autismandan
rss-ronden
tyngre-radio
rss-traningsklubben